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PERSPECTIVE Open Access
Are there sufficient standards for the in vitro
hemocompatibility testing of biomaterials?
Steffen Braune1, Michael Grunze2, Andreas Straub3 and Friedrich Jung1*
In this perspective we address a fundamental and unre-
solved issue in biomaterials science: What are the mo-
lecular mechanisms which make a material blood
compatible - or not? Despite the widespread use and the
billion-dollar industry producing medical devices and
implants, there is still a lack of fundamental understand-
ing of the –admittedly– complicated and interlinked re-
actions that occur when an artificial material is exposed
to blood. The increasing number of clinical reports
about in vivo dysfunctional cardiovascular devices
underlines the importance to understand –and be able
to predict– the pathophysiological events occurring
upon contact of blood with “hemocompatible” materials.
The missing knowledge about the pathophysiological
processes in the material/blood interphase and the
lack of reliable correlations between in vitro-in vivo
experiments, hinders us to develop scientific design
principles to avoid complications in a clinical situation
and achieve the optimal and lasting treatment. One may
ask why this is the case, despite the huge research efforts
taking place in laboratories worldwide to improve exist-
ing biomaterials and to develop new and better ones.
One reason is certainly the analytical, intellectual and fi-
nancial efforts it takes to unravel the interlinked bio-
chemical reactions taking place in the interphase
between the material and the body. But what actually
slows the scientific community from developing models
and theories on hemocompatibility is the fact that hardly
any publication targeted at developing hemocompatible
biomaterials conducts and describes the experiments
and results in enough detail to allow a direct comparison
to data in the literature or results of other laboratories.
The lack of defined and certified positive or negative stan-
dards and experimental protocols even prevents us from
concluding if a material is relatively better than another
material, which may or may not be in use in medical
practice. Hence, the literature is full with claims for “new”
or “better” biomaterials, which have not undergone an
in vitro side by side comparison to a standard, nor animal
tests or clinical evaluation. If such in vitro comparisons
with accepted standards would be performed according to
standardized protocols, respective reports could contribute
in a meaningful way to a database, which ultimately would
provide the basis for a roadmap to better implants.
This perspective is written to remind the reader of the
complicated and interlinked reactions taking place on a
material surface upon contact with blood, which may lead
to inflammation and thrombosis. It is not our intention to
give a comprehensive review on hemocompatibility test-
ing, but to emphasize the challenges in establishing inter-
national standards in this area of biomaterial research and
to motivate the academic community to define the re-
quired standards for their own benefit and for this re-
search area in general.
Background
The increasing age of populations in industrialized na-
tions - together with a lack of physical activity and chan-
ged diet habits - are associated with an increase of
atherosclerotic diseases causing high morbidity and mortal-
ity [1]. Atherosclerosis is caused by a complex interplay of
endothelial dysfunction, lipid disturbances, platelet activa-
tion, thrombosis, oxidative stress, vascular smooth muscle
activation, altered matrix metabolism, re-modelling, genetic
factors, and inflammation [2]. These phenomena cause
plaque formation in arterial walls, which leads to a progres-
sive narrowing of the arterial lumen and an insufficient sup-
ply of the adjacent tissue with oxygen and nutrients.
Atherosclerotic diseases still cannot be cured and, till today,
about 50% of the population of industrial nations die from
cardiovascular diseases. To restore sufficient blood flow in
diseased arteries, balloon catheters with or without the im-
plantation of endovascular stents [3,4] are routinely applied.
These cardiovascular implants are selected and designed to
be hemocompatible in order to fulfil their function. How-
ever, specific drawbacks limit their use, such as: long-term
* Correspondence: Friedrich.Jung@hzg.de
1Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative
Therapies, Helmholtz-Zentrum Geesthacht, Kantstrasse 55, Teltow 14513,
Germany
Full list of author information is available at the end of the article
© 2013 Braune et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
in any medium, provided the original work is properly cited.
Braune et al. Biointerphases 2013, 8:33
http://www.biointerphases.com/content/8/1/33
endothelial dysfunction, delayed re-endothelialization,
thrombogenicity and embolization, permanent physical irri-
tation, inflammation at the implantation site, as well as
non-permissive or disadvantageous characteristics for later
surgical revascularization [5,6]. The resulting thrombotic
occlusion can lead to total implant failure, as it is observed,
for instance, as late in stent thrombosis for drug-eluting
stents [7,8]. Similar undesired phenomena are reported for
other cardiovascular implants and blood-contacting devices
made of metals, polymers, and other artificial materials in-
cluding vascular grafts, occluder systems, heart valves, ven-
tricular assist devices, heart-lung machines, etc. [9-13].
In the complex and dynamic process of blood-material
interaction, the composition of immediately adsorbed pro-
tein layers, but also conformational changes of surface
adsorbed proteins are considered to substantially influence
the cellular interactions (by the exposure of neo/cryptic
epitopes) [14-18]. Key elements of the latter are blood
platelets, which play a central role in physiological and
pathological processes of hemostasis, inflammation, tumor-
metastasis, wound healing, and host defence [19-24]. An
understanding of the interactions of proteins, platelets and
the surfaces of blood contacting biomaterials is, conse-
quently, crucial if we aim to identify and design truly hemo-
compatible biomaterials.
Despite many years of research, the detailed mechanisms
of pro-coagulatory and pro-inflammatory events upon
blood contact with artificial surfaces are only poorly under-
stood [25,26]. This lacking knowledge, the absence of com-
mon standards in the in vitro testing and the missing
consensus of what makes a material blood incompatible
in vivo has led to the term “blood compatibility catastro-
phe” (coined by Buddy Ratner) [27,28]. Although standards
for hemocompatibility testing are defined in the ISO
10993–4, this catalogue comprises minimum test require-
ments only and supplementary tests need to be performed
[29]. A standardized in vitro hemocompatibility test panel
should enable the detection and elimination of undesired
and excessive material-induced thrombosis and inflamma-
tory events at an early stage of biomaterial development.
In the following, we discuss currently applied approaches
and suggest practises and standards for in vitro hemocom-
patibility testing. If we want to understand the complex
interplay and the underlying pathophysiological mecha-
nisms, both players, the biomaterial surface and the blood
cells/components, need to be thoroughly studied and their
interactions require characterization in greatest possible de-
tail. Moreover, knowledge about origin and composition
and, ultimately, the genetic fingerprint of the donor may
prospectively lead towards a more “personalized” medicine.
Characterization of the material surface
The analytical and surface science methods which can
be used to quantitatively analyze the implant material
surfaces ex situ are well described in the literature, in
particular with respect to biomaterials characterization
in the book edited by Ratner et al. [26]. Surface analysis
can routinely specify the elemental and chemical com-
position of the surface with a few percent accuracy using
X-ray photoelectron spectroscopy (XPS), secondary ion
spectroscopy (SIMS) and, in the case of polymers, with
vibrational spectroscopies such as infrared absorption
spectroscopy (IR) and RAMAN spectroscopy. The iden-
tification of minority species on the surface which may
cause inflammatory events, however, is more difficult to
access but equally important. Also, the potential of im-
purity diffusion (e.g. solvent residues in polymers) from
the bulk to the blood contacting surface should be care-
fully checked. It is therefore highly desirable to confirm
also the bulk composition, and to determine any concen-
tration gradients in composition (e.g. in alloys or polymer
blends) from the bulk to the interface. Depth profiling
is done by angle dependent measurements in XPS, but
also by changing the photon energies or the detection
mode (electrons or photons) when synchrotron radi-
ation is used.
It is quite common that the bulk composition of alloys
deviates considerably from batch to batch, and that poly-
mers and polymer mixtures contain softeners and solv-
ent residues. This means that an unexpected surface
composition is not necessarily due to contaminations or
segregation; it could be that the material is of different
composition than expected. Hence, for commercial ma-
terials the composition information provided by the sup-
plier should be checked for every batch of samples used.
It has also to be considered that measuring the surface
composition of a material in vacuum (e.g. when using
electron spectroscopies) or in an ambient atmosphere (e.g.
vibrational spectroscopies) does not necessarily reflect
the surface composition (and morphology) in an aqueous
environment or blood. In situ measurements in aqueous
solutions are much more complicated -if not impos-
sible in some cases- and require specialized instruments
(e.g. nonlinear optical techniques) not readily available in
most laboratories.
However, it is not only the chemical make-up of the inter-
face, which is important. Inflammatory and pro-coagulant
processes can be induced by intrinsic physical biomaterial
properties such as porosity, roughness, charge and charge
density, elasticity, or surface energy (wettability) [30-32].
Therefore, a profound physical-chemical characterization of
the material properties is mandatory and required for
the interpretation of material-protein as well as material-
cell interactions. Water wettability is a routinely deter-
mined and important parameter, but not an indicator if a
surface is biocompatible or not. More relevant is the sur-
face energy, measured by the contact angle of several liq-
uids [33]. The measurements on the physical properties of
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the materials surface should be done in a dry and a hy-
drated state, since contact with aqueous solutions will lead
to swelling of most polymers and, hence, to a different
morphology and stiffness, or in the case of polymer mix-
tures and block-copolymers to a different surface compos-
ition. All these parameters should be measured under
standardized conditions after sterilization, and selectively
confirmed before application of the implant. The latter is
in particular true for materials that are prone to oxidation
in air, which will lead to a change in surface composition.
A hydrocarbon contamination layer adsorbed from the
ambient can also influence the initial reaction with bodily
fluids. A quick indicator for changes in surface compos-
ition is, for example, the water contact angle.
It is recommended to characterize representative sam-
ples for their general properties after preparation, and,
importantly, prior to the actual experiments, after final
cleaning steps and sterilization [34]. All mechanical, sur-
face morphology, and roughness measurements should
be done after preparation. Surface composition should
be checked on samples that underwent final cleaning
and sterilization since the latter can majorly influence
the material properties [35].
The chemical composition of the bulk material and
the surface layer has to be specified as precisely as pos-
sible. Surface composition conveniently is measured with
the instruments available at the laboratory; however, an
XPS analysis of the surface is required as an absolute
measurement of composition and for cross calibration of
other characterization methods. Mandatory is that the
conditions under which the measurements were taken
are meticulously specified (e.g. for XPS: X-ray source,
power, photon energy, instrumental resolution, photon
incidence angle, take of angle, vacuum conditions, statis-
tics of the measurements with error margins, indications
of radiation damage, …) and the methods and assump-
tions used to determine surface concentrations and
depth distributions are described in sufficient detail. It
has to be checked if the distribution of elements or func-
tional groups is homogeneous, or patchy. Polymer sur-
faces should be characterized by IR and RAMAN
spectra, including an assignment of the vibrational
bands. If there are questions about the surface compos-
ition, a deconvolution of the spectra is needed for a con-
sistent assignment of absorption bands.
Before exposure to the biological medium, a final check
of the water contact angle, and comparison of the value to
the contact angle measured on the pristine and cleaned
material, is an ambiguous but useful indicator if the
surface has been contaminated by impurities.
In an ideal setting, the materials under study will be
tested side by side to an established and defined materials
standard. Only a combination of cross-calibrated surface
analysis techniques can possibly establish a correlation
between surface characteristics and hemocompatibility. In
order to have a final judgment which techniques are most
useful and essential to make a correlation between surface
properties and hemocompatibility, a comparative study
under standardized conditions of different materials has to
be done. The more information is available about the sur-
face, the easier it will be to make a comparison to other
data and identify possible small but subtle differences in
composition, which are then amplified in the hemocom-
patibility tests.
Endotoxin testing
It is well known that polymer-based biomaterials can be
contaminated e.g. with pyrogenic substances including en-
dotoxins and other microbial products [36-38]. Such sub-
stances may lead to non-specific immune reactions that
can be characterized by e.g. macrophage activation, the
generation of reactive oxygen species (ROS), activation of
the complement system and the secretion of inflammatory
cytokines from leukocytes [39]. The cellular response of
immune cells towards microbial products is mediated by
engagement of toll-like receptors, which are expressed on
leukocytes and platelets [40,41]. Particularly, the binding
of endotoxins to TLR4, the receptor for endotoxins,
can result in the secretion of pro-inflammatory media-
tors and activation of inflammatory cells.
It strictly needs to be proven that candidate implant ma-
terials are free of soluble as well as of material-adherent
microbial products. Failing this, contaminations of the
material may lead to an erroneous evaluation of the mate-
rial’s hemo- and/or tissue-compatibility. Free soluble
endotoxins can be routinely assessed, e.g. by commercially
available and well established Limulus Amebocyte Lysate
(LAL) based tests systems [37,38]. In addition, material-
bound endotoxins should be determined, for instance,
utilizing cell-based assays that analyse the viability and ac-
tivation (cytokine secretion) of macrophages (RAW-blue™
cells) subsequent to direct material contact [36,42]. The
combination of these “indirect” and “direct” test systems
may allow an adequate evaluation of the material endo-
toxins burden [43].
Cytocompatibility testing
Cytotoxicity, the ability of a material to influence cellular
viability (e.g. cell membrane integrity and growth),
should be assessed as a primary biocompatibility test.
International standards for cytotoxicity testing are deter-
mined in the EN DIN ISO standards (especially 10993–
5, 10993–12 and ISO 7405) but, depending on the scien-
tific background of the study, approaches differ clearly
between laboratories. Screening of new candidate bioma-
terials can be performed with material eluates to deter-
mine the release of potentially toxic soluble substances
from the material bulk (indirect test). This approach
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may be well suited for a standardized testing, particularly
in view of high-throughput screenings [44]. Since such
setups are performed independently from the intended
material application, results may be of limited scientific
value but provide the basis for further testing of the dir-
ect cell-material interactions (direct test). In this case,
the selection of site-specific cells (e.g. endothelial cells
and smooth muscle cells) may allow a more application
relevant evaluation of the material performance (e.g. car-
diovascular applications) [45,46]. If a material surface is
intended to inhibit the interaction with proteins and cells
by antifouling properties, the direct setup cannot provide
a reasonable statement and the toxicity has to be evaluated
utilizing the indirect setup [47]. To enable an internal
and inter-institutional comparison, it is recommended to
evaluate the cytotoxicity of materials according to the
above mentioned EN DIN ISO standards. Two test proce-
dures are suggested: test of material extracts on adherent
cells, e.g. L929 mouse fibroblast (indirect test) and, in
addition, tests with direct contact of material and cells
(direct test) [34,48,49]. For an indirect testing, polymer
samples are exposed to serum-free cell culture medium
under continuous stirring at 37 °C for three days. The
resulting extract replaces the cell culture medium for
L929 cells, which are seeded on polystyrene-based cell cul-
ture plates and are allowed to grow a sub-confluent layer.
After 48 hours of incubation, cell morphology (e.g. phase-
contrast microscopy), the viability of the cells (e.g. fluores-
cein diacetate/propidium iodide assay), integrity of the cell
membrane (e.g. lactate dehydrogenase assay) and mito-
chondrial activity (e.g. MTS tetrazolium assay) is analysed.
For direct testing, material samples are inserted in multi-
well plates and seeded with cells. After reaching 80% con-
fluence, assays are performed according to the indirect
setup. Obtained results can be transformed in an assay-
based and final score, which allows the discrimination of
non-toxic and cytotoxic materials. Tissue culture treated
polystyrene surfaces (negative) and Triton® X-100 treated
cells (positive) can be applied as controls, independently
from other, more specific, assay internal reference mate-
rials [45,50].
Hemocompatibility testing
As required by regulatory agencies, the hemocompatibil-
ity of biomaterials for medical devices has to be evalu-
ated conforming standards defined in the ISO 10993–4.
Thrombosis, however, is still noted in many of the clinic-
ally applied devices. The approval by the currently rec-
ommended panel of tests, consequently, does not
guarantee clinical device/biomaterial hemocompatibility,
which emphasized the major need for improved and
in vivo predictive in vitro test setups. Unsolved concerns
are also the lacking standards for anticoagulation or ref-
erence materials. Thus, variations between studies hardly
enable a classification of hemocompatible and non-
hemocompatible materials [51].
Anticoagulation of blood samples is mandatory in order
to avoid spontaneous coagulation processes in vitro. Func-
tional aspects of various anticoagulants have been reviewed
extensively and are therefore not part of this perspective
[52-54]. Most commonly used anticoagulants are heparin
for whole blood studies and sodium citrate for studies that
focus on platelet-biomaterial interactions in vitro [52,55].
More recently, hirudin appears in an increasing number of
hemocompatibility studies and clinically applied routine
test systems [56,57]. The decision for a specific anticoagu-
lant should be driven by the clinical background, the choice
of tested blood (e.g. whole blood, platelet rich plasma (PRP)
or platelet poor plasma (PPP)) and the specific scientific
questions of the study (e.g. basic screening of various mate-
rials or comprehensive investigation of the inflammatory
and coagulatory potential of one material). In addition, it is
crucial to determine and standardize the appropriate con-
centrations of the respective anticoagulant to ensure the
functionality of blood cells and blood components, but also
to minimize the inhibition of coagulation activation in the
in vitro test system. No internationally accepted guidelines
are established that define appropriate concentrations for
anticoagulants used in the in vitro evaluation of biomaterial’s
hemocompatibility. Therefore, a strong need exists to
define these parameters to enable an inter-institutional
comparison of different studies and materials.
Heparin is routinely applied as systemic anticoagulant
in many therapeutic approaches and, therefore, applied
by many laboratories to investigate the hemocompatibil-
ity of biomaterials in whole blood studies. However, no
common standard is established for heparin and differ-
ent functional forms e.g. unfractionated heparin (UFH),
low molecular weight heparin (LMWH) or pentasaccha-
ride types (e.g. Fondaparinux) [58,59] are applied in
varying concentrations (0.5 IU to 5 IU heparin per mL
blood) [60-64]. For PRP based assays, concentrations of
0.105 – 0.109 M and 0.129 M tri-sodium citrate are
recommended by the British Committee for Standards
in Haematology (BCSH) and International Society on
Thrombosis and Haemostasis (ISTH) [65-67]. These
assays focus on the platelet-biomaterial interactions and
are well suited to assess the thrombogenic potential of a
material, even though, sodium citrate is not applied as
a systemic anticoagulant. For in vitro studies focusing
on complement activation, anticoagulation with hirudin
(commercially available as lepirudin or bivalirudine [68])
appears to mimic physiological conditions more appro-
priately than other anticoagulants [56,57,69].
Standardized hemocompatibility testing is usually per-
formed with blood from healthy subjects, which should be
stringently characterized, free of medication (particularly
platelet function inhibitors), should be non-smokers, avoid
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vigorous exercise as well as certain nutrition that is known
to influence platelet function [52]. Material systems at an
advanced stage of development should additionally be
tested with blood from the target-patient group to study
how the disease and the therapeutical medication influ-
ence the material properties and if the functionality of the
device is modified [70].
Guidelines for blood collection and preparation are ex-
tensively described in the ISTH and BCSH-guidelines
[65,66,71]. The latter recommend minimizing venostasis
during blood withdrawal, the use of a needle of 21 gauge
and the collection of blood into plastic (polypropylene) or
siliconized glass tubes. Despite recent studies question the
necessity of a discard tube, it is further noted that the first
3 – 4 mL of blood are not suitable for testing due to the
potential coagulation activation by e.g. tissue factor
(thromboplastin) in the syringe [72-74]. Subsequent to the
blood withdrawal and prior to the final test, blood samples
should rest for at least 30 minutes under mild agitation,
since platelet function, particularly platelet aggregation
can be reduced immediately after blood collection [75].
The total test duration should not exceed 4 hours to en-
sure an appropriate function of blood cells and blood
plasma proteins [29,76-80].
Pre-analytical blood testing should be routinely carried
out to verify the suitability of blood donors. Participants
who exhibit latent inflammation, an altered platelet func-
tion or platelet disorders can, thus, be excluded [52].
Pre-tests should, at least, comprise haemogram-analysis,
acute-phase protein determination as well as spontaneous
and induced platelet function analysis.
Recommendations for a further preparation of whole
blood comprise the sourcing of PRP and cell poor plasma
and are summarized in the international guidelines for
thrombosis and haemostasis testing [65,66,71,81,82]. These
guidelines recommend that blood preparation should be
carried out at room temperature and variations in
temperature should be avoided due to the activation of
blood cells at decreased temperatures [83,84]. However,
there is evidence to suggest that a temperature of 37 °C,
constantly kept during the blood withdrawal, storage and
preparation as well as during the final assay, may reflect the
in vivo situation even more appropriately [85-87].
Currently, various in vitro static and dynamic test sys-
tems are applied to evaluate the hemocompatibility of bio-
materials. Tests under static conditions were earlier
developed by Breddin to determine platelet spreading as
a diagnostic and prognostic marker for platelet disorders,
e.g. thrombocytopenia [88]. More recently, this method
was adapted for hemocompatibility screening studies [89]
and further modified and automated for thrombogenic
materials [90-92]. Static test systems simulate low flow or
even no flow areas in the vasculature and provide a rapid
and sensitive setup to determine the thrombogenicity of a
biomaterial, in particular platelet adhesion. Dynamic sys-
tems are more appropriate to simulate the conditions in
flowing whole blood in vivo or of extracorporeal devices
and allow an adaptation of the test conditions to the (pa-
tho-) physiological situation of specific medical devices
[93,94]. Different setups are currently used including: agi-
tators, centrifugation systems, flow chambers, chandler
systems and closed loop circulation models. However, in-
formation about the test conditions and reproducibility
are required but lacking for many of these systems. An ap-
propriate dynamic model should simulate the arterial or
venous conditions of blood/material interactions during
the clinical application. Size and geometry of the device,
duration of contact (up to 240 minutes), temperature as
well as rheological (flow) and shear conditions should be
considered in the design of the setup [29,52,70]. If a
miniaturization of the device is required, blood flow
should be proportionally adjusted to the reduced material
surface area in order to adapt the degree of mechanically
induced shear forces [70]. In studies focusing on platelet-
material interactions, elevated shear forces (> 50 N • m-2),
as well as recalcification of citrated blood samples or air in
the test system may artificially induce platelet activation/
aggregation and should be avoided to ensure an accurate
determination of thrombogenic effects induced explicitly
by the material surfaces and not by the experimental con-
ditions [95-97]. Especially in the dynamic test systems,
kinetic measurements should preferentially be performed
instead of endpoint determinations to characterize the
time-dependence of blood/material interactions.
To classify a material hemocompatible, reference mate-
rials have to be defined, which enable the discrimination
between known hemocompatible materials and non-
hemocompatible materials. Respective reference materials
were recommended in earlier national or international
consensus initiatives [98-100]. Unfortunately, these mate-
rials are not frequently used, in part not commercially
available and may also not represent current state-of-the-
art technology. As a consequence, a variety of references
aside of the recommended materials (filler free polydi-
methylsiloxan, low density polyethylene, polyvinylchloride,
polyurethane, cellulose and expanded polytetrafluorethy-
len) have been applied in recent studies [51,100,101].
To overcome these problems, one promising approach
may be to determine the reference materials in view of
the clinically applied gold standards. This primarily al-
lows an application specific comparison but potentially
is also suitable for standardization in basic screening
studies. In the context of positive controls, efforts were
made to establish polyacrylate-based materials, which
strongly interact with human platelets [102]. Alterna-
tively, collagen coated glass or polystyrene, also served
as an appropriate and standardized positive control. In
order to allow an inter-study and inter-institutional
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comparison, routine controls as used in clinical chemistry
and hematology have to be performed for each test
parameter [103-105]. In test setups that focus on the inter-
action of blood with eluates or micro- and nano-particles,
the use of soluble pro-coagulatory substances e.g. thrombin
or ADP may be appropriate [106,107].
The use of a score system, as suggested by Seyfert (single
test scores are summarized in a total score to evaluate the
hemocompatibility of the sample), might further help to
standardize the in vitro hemocompatibility testing of bio-
materials [29]. Alternatively, acceptance criteria can be ap-
plied with comparison to a predicate type material. The
criteria can be expressed as percentage of baseline and
should, at least, include hemolysis, thrombosis (platelet
covered surface area), platelet retention/count as well as
coagulation time [51].
As a consequence of the currently recommended but
insufficient test panel defined in the ISO norm, further
tests should be considered for assessing hemocompat-
ibility of biomaterials.
In order to understand which specific plasma proteins
are primarily adsorbed by respective surfaces, adsorption
profiles of proteins can be recorded using ELISA and/or
western blotting techniques [16,108-111]. Further com-
prehensive test collections reported by Seyfert et al.
comprise tests for the following aspects: contact activation,
fibrinogen-fibrin conversion, fibrinolysis, hemolysis, prote-
olysis, and platelet activation [29]. In addition to these tests,
also the activation of the plasmatic coagulation (e.g. quanti-
fied by the measurement of thrombin-antithrombin com-
plexes and/or prothrombin fragments 1 + 2 [112]) as well
as the interaction of granulocytes, monocytes and lympho-
cytes with the biomaterial surface might be beneficial to
understand the complex interplay between thrombotic and
inflammatory processes [113]. In this context, also whole
blood cytokine secretion and complement activation assays
can be applied to clarify whether the thrombotic potential
of a material is induced directly by the adhesion of platelets
or by alternative inflammatory pathways [42,114]. As an ex-
ample, complement factors (e.g. C5b-9) but also platelet ag-
onists including thrombin and collagen support the
shedding of procoagulant and proinflammatory microvesi-
cles from the platelet surface, which show similar surface
expression of activation dependent adhesion molecules
(P-selectin, CD40L) as stimulated platelets [115-117].
Aside from the basic hemocompatibility screening, a
fundamental understanding of the interactions between
blood cells/components and body foreign surfaces is
needed. Therefore, systematic studies have to be carried
out, focusing the influence of distinct material properties
on a molecular level. Knowledge about the material in-
duced outside-in signal transduction may allow new ma-
terial design approaches, which could provide improved
hemocompatible surfaces. In the clinical situation, this
could enable cessation or at least dose reductions of
anti-platelet/anticoagulatory treatment regimens like for
example after coronary artery stenting, where platelet
inhibitors are administered or in ventricular assist devices
(VAD) patients, where heparin, warfarin, phenprocoumon
and platelet inhibitors are employed [118,119]. Thereby,
life-threatening bleeding complications in these patient
groups could be strongly reduced. In addition to an im-
provement of the properties of blood-contacting materials,
the development of new antithrombotic therapies based
on the blocking of undesired pathways with potentially
less bleeding complications compared to current treat-
ment strategies may also be conceivable [120].
Conclusion
This perspective pointed out some serious deficiencies in
our understanding of “hemocompatibility” and summa-
rized current approaches for in vitro hemocompatibility
testing. While it is widely accepted that the standards
given in the EN ISO 10993-4/5 are minimum require-
ments, it is still under debate which supplementary tests
have to be performed for understanding the interaction
between blood cells/components and artificial surfaces. To
exclude activation of coagulatory and inflammatory pro-
cesses induced by manufacturing processes of the candi-
date materials, standards for the preparation and
characterization need to be defined that involve cleaning,
sterilization, endotoxin determination as well as a pro-
found physical-chemical characterization. Currently, there
is no agreement which anticoagulant in which concentra-
tion should be used and what kind of pre-analytical test
should be routinely performed to characterize and proof
the functionality/suitability of the donated blood. Also, the
choice of common reference materials for positive and
negative controls has to be redefined, since materials sug-
gested in earlier consensus papers may not represent state
of the art technology or are not commercially available.
Therefore, the main question of our manuscript- namely
whether there are sufficient standards for hemocompat-
ibility testing of biomaterials -needs to be answered with
“no” at the current point of time. A consensus in the above
mentioned matters is highly desirable and a prerequisite
for an internal and inter-institutional comparison of hemo-
compatibility studies as performed in clinical chemistry and
heamatology. Moreover, a common approach may help to
improve the in vivo predictability of in vitro hemocompat-
ibility studies and, hopefully, will lead to a better under-
standing and advanced design of artificial biomaterials.
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